FDA to lift clinical hold on Stem Cell Therapeutics' phase-IIb stroke trial
Stem Cell Therapeutics Corp announced that the US Food and Drug Administration (FDA) has provided a verbal confirmation to remove its clinical hold placed on NTx-265 on September 18, 2008. This will allow SCT to commence the recruitment of patients under an amended protocol using NTx-265 for the company’s phase-IIb clinical trial treating acute ischemic stroke.
[Read the full article here]Related News:
Stem Cell Therapeutics Corp. Announces The FDA Has Lifted Its Clinical Hold On The Phase IIb Stroke Trial
Stem Cell Therapeutics Corp. Announces Top-Line Results for the Modified REGENESIS Phase IIb Stroke Trial
DSMB recommends Stem Cell Therapeutics for phase-IIb acute ischemic stroke trial